TG Therapeutics Reports Third Quarter 2024 Financial Results and Raises BRIUMVI® (ublituximab-xiiy) Full Year Revenue Guidance
November 04, 2024 07:00 ET
|
TG Therapeutics, Inc.
Third quarter 2024 U.S. BRIUMVI net revenue of $83.3 million Raises full year 2024 U.S. BRIUMVI net revenue target to $300 - $305 million Conference call to be held today, November 4, 2024,...
TG Therapeutics to Host Conference Call on Third Quarter 2024 Financial Results and Business Update
November 01, 2024 08:06 ET
|
TG Therapeutics, Inc.
NEW YORK, Nov. 01, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held, Monday November 4, 2024, at 8:30 AM ET to discuss results for...
New BRIUMVI® (ublituximab-xiiy) Data from the ENHANCE Phase 3b Study Show Rapid 30-Minute Infusions are Well Tolerated in Patients with Relapsing Forms of Multiple Sclerosis
September 18, 2024 07:15 ET
|
TG Therapeutics, Inc.
Infusion related reactions in patients receiving 30-minute BRIUMVI infusions were all mild (Grade 1) and resolved completely Data also demonstrate patients switching from prior anti-CD20 treatment...
New Data for BRIUMVI® (ublituximab-xiiy) Demonstrate that 92% of Patients with Relapsing Multiple Sclerosis Were Free from Disability Progression After 5 Years of Treatment
September 18, 2024 07:00 ET
|
TG Therapeutics, Inc.
During year 5 of treatment with BRIUMVI the annualized relapse rate was 0.020, equivalent to one relapse occurring every 50 years of patient treatment Overall safety profile of BRIUMVI remained...
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI at the 2024 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting
September 05, 2024 07:30 ET
|
TG Therapeutics, Inc.
NEW YORK, Sept. 05, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of upcoming data presentations, highlighting data from both the ULTIMATE I & II...
TG Therapeutics Reports Second Quarter 2024 Financial Results and Raises BRIUMVI® (ublituximab-xiiy) Full Year Revenue Guidance
August 06, 2024 07:00 ET
|
TG Therapeutics, Inc.
Second quarter 2024 U.S. BRIUMVI net revenue of $72.6 million Raising full year 2024 U.S. BRIUMVI net revenue target to approximately $290 - $300 million Cash flow positive for second quarter 2024 ...
TG Therapeutics to Host Conference Call on Second Quarter 2024 Financial Results and Business Update
August 05, 2024 07:30 ET
|
TG Therapeutics, Inc.
NEW YORK, Aug. 05, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held, Tuesday August 6, 2024 at 8:30 AM ET to discuss results for the...
TG Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
June 07, 2024 07:50 ET
|
TG Therapeutics, Inc.
NEW YORK, June 07, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the...
TG Therapeutics to Participate in the Jefferies Global Healthcare Conference
June 03, 2024 07:30 ET
|
TG Therapeutics, Inc.
NEW YORK, June 03, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the...
TG Therapeutics Announces Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the 2024 Consortium of Multiple Sclerosis Centers Annual Meeting
May 31, 2024 07:30 ET
|
TG Therapeutics, Inc.
NEW YORK, May 31, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced presentations highlighting study designs for post-marketing studies being undertaken for...